Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

[1]  Keith A. Johnson,et al.  Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. , 2022, JAMA neurology.

[2]  O. Hansson,et al.  Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials , 2022, The Lancet Neurology.

[3]  R. Sperling,et al.  Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. , 2022, JAMA neurology.

[4]  Alexa Pichet Binette,et al.  Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease , 2021, JAMA neurology.

[5]  G. Kerchner,et al.  Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease , 2021, Alzheimer's research & therapy.

[6]  A. Nordberg,et al.  Alzheimer’s disease spectrum profiled by CSF and imaging biomarkers: Tau PET best predicts cognitive decline , 2021, Alzheimer's & Dementia.

[7]  A. Nordberg,et al.  Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline , 2021, Molecular Psychiatry.

[8]  Nick C Fox,et al.  Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study , 2021, Translational Psychiatry.

[9]  M. Dichgans,et al.  Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals , 2021, Alzheimer's research & therapy.

[10]  W. Jagust,et al.  Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease , 2021, JAMA neurology.

[11]  Joanne S. Robertson,et al.  Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease , 2021, Journal of Alzheimer's disease reports.

[12]  L. Schneider,et al.  Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group , 2021, The Lancet Neurology.

[13]  V. Lowe,et al.  Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[14]  Philip S. Insel,et al.  Early stages of tau pathology and its associations with functional connectivity, atrophy and memory , 2021, Brain : a journal of neurology.

[15]  K. Blennow,et al.  2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  G. Frisoni,et al.  Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  K. Blennow,et al.  Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures , 2021, Nature Medicine.

[18]  Muhammad Naveed Iqbal Qureshi,et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.

[19]  F. Schmitt,et al.  Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. , 2020, JAMA neurology.

[20]  O. Hansson,et al.  Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.

[21]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[22]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[23]  Nick C Fox,et al.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease , 2020, Nature Medicine.

[24]  Timothy J. Hohman,et al.  Genetic variants and functional pathways associated with resilience to Alzheimer’s disease , 2020, bioRxiv.

[25]  C. Jack,et al.  Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study , 2019, The Journal of Nuclear Medicine.

[26]  Philip S. Insel,et al.  Determining clinically meaningful decline in preclinical Alzheimer disease , 2019, Neurology.

[27]  David T. Jones,et al.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. , 2019, JAMA.

[28]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[29]  Stephen Salloway,et al.  A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia , 2019, Brain : a journal of neurology.

[30]  Clifford R Jack,et al.  Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers , 2019, Brain : a journal of neurology.

[31]  Philip S. Insel,et al.  Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease , 2019, Neurology.

[32]  Keith A. Johnson,et al.  The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals , 2018, Annals of neurology.

[33]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[34]  Y. Stern,et al.  Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance , 2018, Alzheimer's & Dementia.

[35]  W. M. van der Flier,et al.  Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results , 2018, Alzheimer's Research & Therapy.

[36]  Ron Brookmeyer,et al.  Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease , 2018, Alzheimer's & Dementia.

[37]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[38]  H. Benali,et al.  Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study , 2019 .

[39]  Ronald C. Petersen,et al.  Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.

[40]  R. Sperling,et al.  Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5 , 2017, Alzheimer's & dementia.

[41]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[42]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[43]  Reisa A. Sperling,et al.  Harvard Aging Brain Study: Dataset and accessibility , 2017, NeuroImage.

[44]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[45]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[46]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[47]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[48]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[49]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[50]  Cindee M. Madison,et al.  Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? , 2014, Cerebral cortex.

[51]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[52]  C. Jack,et al.  Effect of lifestyle activities on alzheimer disease biomarkers and cognition , 2012, Annals of neurology.

[53]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[54]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[55]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[56]  C. Junghans,et al.  Consent bias in research: how to avoid it , 2007, Heart.

[57]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[58]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[59]  OUP accepted manuscript , 2022, Brain Communications.

[60]  Maja O’Connor,et al.  A Longitudinal Study , 2013 .

[61]  A. R.,et al.  Review of literature , 1951, American Potato Journal.

[62]  J. Opitz,et al.  Recommendations of an International Working Group , 1982 .

[63]  N. Khoriaty.  How to Avoid It , 1980 .